Here, our research highlighted that in cancer cells with high level of MUC1, the referenced dosage and actual cytotoxicity of clinical drugs need to be modulated according to the level of MUC1 O-glycosylation, especially in BRCA and PAAD. This evidence concerns the gene MUC1 and cancer.